700-45-8

Usage

Uses

Used in Pharmaceutical Industry:
5-Fluoro-1,2,3,4-tetrahydronaphthalene is used as a key intermediate in the synthesis of sulfonamides, which are a class of antimicrobial agents. These sulfonamides act as inhibitors of the chemokine receptor CCR8, playing a crucial role in the treatment of eosinophil and Th2-mediated diseases.
Used in Treatment of Eosinophil and Th2-Mediated Diseases:
5-Fluoro-1,2,3,4-tetrahydronaphthalene is used as a building block for the development of drugs targeting eosinophil and Th2-mediated diseases such as asthma, allergic dermatitis, and rheumatoid arthritis. By inhibiting the chemokine receptor CCR8, these drugs can help regulate the immune response and alleviate the symptoms associated with these conditions.

Upstream product

• 628731-58-8 8-fluoro-3,4-dihydronaphthalene-1(2H)-one 
• 321-38-0 1-Fluoronaphthalene 
• 2217-40-5 1,2,3,4-tetrahydronaphthalen-1-amine 
• 2217-41-6 1-amino-5,6,7,8-tetrahydronaphthalene 
• 540-80-7 tert.-butylnitrite 

Downstream Products

• 298197-80-5 trans-fluorodecalin 
• 298197-80-5 1-fluoro(ax)-cis-decalin 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE

The present disclosure is directed to adenine analogs, methods of making adenine analogs, and methods of treating disorders associated with PINK1 kinase activity including, but not limited to, neurodegenerative diseases, mitochondrial diseases, fibrosis,

Tuning chemical compositions of bimetallic AuPd catalysts for selective catalytic hydrogenation of halogenated quinolines

Catalytic hydrogenation of halogenated quinolines is a longstanding challenge due to the harsh reaction conditions and disillusionary chemoselectivity owing to dehalogenation. Exploration of novel catalytic materials is still a big challenge. Herein, density functional theory calculations indicate that halogenated quinolines are selectively adsorbed on the Au surface via the nitrogen atom in the tilted orientation and on Pd via the quinoline ring in the flat orientation. In the tilted orientation, the C-Cl bond is away from the surface of catalysts, which can avoid the hydrogenation of the C-Cl bond by the surface activated hydrogen species. A series of Au1?xPdx bimetallic catalysts were deposited on CeO2 nanorods by a facile electroless chemical deposition method. The Au1?xPdx catalysts with low Pd content delivered enhanced activity and improved chemoselectivity for the hydrogenation of halogenated quinolines. Highly dispersed Pd in the Au matrix of bimetallic catalysts with low Pd content triggers hydrogen activation on Pd sites and leads to the selective adsorption of halogenated quinolines on Au sites in the tilted orientation. The generated active hydrogen species can diffuse from Pd to Au sites for the hydrogenation of the tilted halogenated quinolines, resulting in suppressed dehalogenation and high chemoselectivity to the expected products.

ARYL SULFONAMIDES USEFUL AS INHIBITORS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention provides compounds of general formula I: or a pharmaceutically acceptable salt thereof, wherein R1, X, Z, R2, X., Ar, n, R3 and R4 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR8 and acc

CCR8 INHIBITORS

Disclosed are CCR8 inhibitors represented by Structural Formulas (I). The variables in Structural Formula (I) are described herein. Also disclosed are methods of treating a subject with a CCR8 mediated condition, especially asthma, by administering one of the disclosed CCR8 inhibitors to the subject.

CCR8 INHIBITORS

Disclosed is an inhibitor of CCR8 that is represented by Structural Formula (I). Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent and a CCR8 inhibitor represented by Structural Formula (I). Also disclosed is a method of treating inflammatory disorders in a subject by administering a CCR8 inhibitor to the subject.